 Company statements 78 Group revenue £88.8m (Loss) earnings per share 2  from  continuing operations (6.7p) Net debt  1 £13.0m Adjusted EBITDA 1 £10.1m 2015 61.7 69.2 88.8 2016 2017 2015 1.3 4.7 (6.7) 2016 2017 2015 9.0 24.6 13.0 2016 2017 2015 12.2 12.5 10.1 2016 2017 2 Quantum Pharma Plc Annual Report and Accounts 2017 Strategic report  A service-led niche  pharmaceutical developer,  manufacturer and supplier to  the health and care sectors The Group operates through three trading divisions incorporating  eight business units across seven locations in the UK and Europe,  offering a portfolio of innovative and synergistic products  and services. 2017 Group revenue 1   breakdown £88.8m 2016 Group revenue 1   breakdown £69.2m The Group’s strategic focus centres on two  key pillars represented by the Specials and  Niche Pharmaceuticals (‘Niche’) divisions. The division also operates  a dedicated aseptics compounding unit that  manufactures bespoke intravenous specials   to order. Niche Develop and supply The Niche division uses this insight into the  specials market, together with other data, to  identify where patient demand for a particular  special is high. These products are assessed  to determine their suitability to enter the Group’s  product development and licensing pipeline. The Niche division benefits from an in-house  product development capability that manages  the Group’s development pipeline alongside   a range of projects for third-party customers. For more  information of the UK’s prescribing hierarchy  and the role of specials and licensed products  within the healthcare industry, turn to page 6. Medication Adherence Homecare and medication management The Group’s visibility over prescribing   trends and growth medicines has been  complemented by the Medication Adherence  division, which dispenses and supplies  medicines into the homecare market and  provides medication management services  through its innovative multi-dose tray system. Around 89%  of unlicensed medicines and special  obtains volumes supplied into the retail and  wholesale pharmacy markets are under  exclusive supply contracts with customers. Sales volumes of imported licensed  medicines into the hospital sector  also grew. • Contract renewals with Phoenix  Healthcare Distribution Limited and  Bestway Panacea Healthcare Limited  (trading as Well the excellent visibility of trends in the UK  pharmacy and hospital markets gained  through the Specials division to supplement  external market data analysis, allowing early  Turn to page 10 to read more about the  actions the Group has taken this year   in the Chief Executive Officer’s review. Last choice Greater risk An extemporaneously  dispensed medicine An imported product  not licensed in the  country of origin Crushing or splitting  licensed tablets  or capsules A non-UK-made  unlicensed medicine  or food supplement 1. http://www.apsm-uk.com/specials-industry.php. 2. Those issued by community pharmacies and excluding those issued from other sources, such as hospital pharmacies. 3. http://www.apsm-uk.com/specials-industry.php. 4. Data covering Scotland unavailable. 5. http://www.apsm-uk.com/specials-industry.php. UK-manufactured  special in  MHRA-licensed  facilities 8 Quantum Pharma Plc Annual Report and Accounts 2017 Strategic report  Business model IN-HOUSE   DEVELOPMENT   & REGULATORY  EXPERTISE OUR POSITIONING OUR BUSINESS MODEL UK Secure & grow International Developing distribution  partnerships Contracted relationships Global sourcing  capability Established UK distribution  network to pharmacies   & hospitals Visibility of   specials market Imported product   licensed in (approved)  country of origin UK-manufactured special in  MHRA-licensed facilities REGULATORY  PATHWAY UK-licensed  medicine PRESCRIBING HIERARCHY CHOICE/ 